Dr Reddys

Dr Reddy's, Lupin recall products in US due to manufacturing errors: USFDA

Dr Reddy's Laboratories and Lupin are recalling products in the US market due to labelling and manufacturing errors, respectively, according to the US health regulator. As per its latest Enforcement Report, US Food and Drug Administration (USFDA) said a US-based subsidiary of the Hyderabad-based drug major is recalling certain batches of a generic antiepileptic drug in the US market. Princeton-based Dr Reddy's Laboratories, Inc is recalling 4,010 bags of Levetiracetam 0.75 pc in Sodium Chloride Injection (1,000 mg/100 mL) in the US due to labelling mix up, USFDA said. "The infusion bag is incorrectly labelled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL," it added. The company has issued the Class 1 nationwide (US) recall on March 13 this year, the US health regulator noted. As per the USFDA, a Class I recall pertains to .

Here's why Dr. Reddy's share slipped 8%, hit 52-week low on Monday, April 7

The fall in Dr. Reddy's share price came after the company announced that it received approximately Rs 2,395-crore show cause notice from I-T department

Senores Pharma to acquire 14 ANDAs from Dr Reddy's for US markets

Gujarat-based Senores Pharmaceuticals on Tuesday said it will acquire a basket of 14 Abbreviated New Drug Applications from Dr Reddy's Laboratories for an undisclosed amount. Senores Pharmaceuticals, Inc, USA, a subsidiary of the drug firm, has inked agreements with Dr Reddy's for acquiring the Abbreviated New Drug Applications (ANDAs), the company said in a statement. The basket includes 13 ANDAs approved by the USFDA (US Food and Drug Administration), with one application pending approval, it added. The addressable opportunity of the acquired ANDAs in the US is around USD 421 million as per IQVIA. Senores said the acquisition will be funded through the initial public offer proceeds. This is in line with the objects of the IPO stated in the Red Herring Prospectus, it added. Senores Pharmaceuticals MD Swapnil Shah said the acquired molecules span multiple therapeutic areas with growing consumption. The portfolio consists of controlled substances and the general category of produ

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Alkem Labs, Ipca, Divi's: Three reasons why pharma stocks are falling today

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

Domestic funds' stake in this stock up over 2900% in FY25; check full list

DIIs have doubled their shareholding, in terms of absolute number of shares held, in 46 out of the Nifty 500 companies in the last nine months, shows ACE equity data.

'Optimistic' about Trump administration, says drugmaker Dr Reddy's

Earlier in the day, the generic drugmaker reported consolidated net profit of Rs 1,414 crore ($163.7 million) for the quarter ended Dec. 31

Dr Reddy's Labs Q3 results: PAT rises 2.5% at Rs 1,413 cr, revenue up 16%

The growth was largely driven by revenue from its recently acquired nicotine replacement therapy (NRT) portfolio and performance in the European and emerging markets

Dr Reddy's Lab Q3 results: Profit up 2.5% at Rs 1,413 cr, revenue rises 16%

Dr Reddy's Lab Q3 results: Shares of Dr Reddy's closed at Rs 1,289.35 on Thursday ahead of its results

Dr Reddy's Labs Q3 Preview: Revlimid to dent US sales, profits may rise 12%

Indian pharmaceutical (IT) major, Dr Reddy's Laboratories, is scheduled to deliver its October-December quarterly earnings for the financial year 2024-25 (Q3FY25) on Thursday, January 23, 2025

Dr. Reddy's pops 4% after Nuvama upgrades to 'Buy'; arm sells US mfg unit

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy' from 'Reduce'

Dr Reddy's up 15% in Dec so far; set for biggest monthly gain since Sep'20

Thus far in the month of December, Dr Reddy's share price has rallied 15%, its biggest monthly rally since September 2020, when it had surged 22%

Nomura's upgrade to 'Buy' lifts Dr Reddy's share over 4% in weak market

The northward move in Dr Reddy's share price came after Tokyo, Japan-based brokerage Nomura upgraded the stock to 'Buy' from 'Neutral'

Kazakhstan authority imposes penalty of Rs 28.7 lakh on Dr Reddy's unit

Dr Reddy's Laboratories on Thursday said Kazakhstan revenue authority has levied a penalty of Rs 28.7 lakh on its subsidiary. The Department of State Revenue, Bostandyk district of Almaty, Kazakhstan has imposed the penalty on Dr Reddy's Laboratories Kazakhstan LLP towards disallowance of claim of certain expenses by the tax authorities for the calendar year 2021, the drug firm said in a regulatory filing. The order levies a penalty of KZT 17,597,212 (Rs 2.87 million), it added. "Based on our evaluation, there is no material impact on the financials, operations, or other activities of the company," the Hyderabad-based drug firm said.

Nifty Pharma jumps over 2%: Analysts decode the drivers behind the rally

Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share

Dr. Reddy's up 2% on launching Toripalimab to treat nasopharyngeal cancer

In 2023, Dr. Reddy's entered into a license and commercialisation agreement with Shanghai Junshi Biosciences Co. Ltd for Toripalimab

Dr Reddy's, FDC recall generic medications in US over manufacturing issues

Dr Reddy's Laboratories and FDC Ltd are recalling generic medications in the US market due to manufacturing issues, according to the US health regulator. As per the latest Enforcement Report by Food and Drug Administration (USFDA), the US-based subsidiary of Dr Reddy's Laboratories is recalling multiple strengths of Morphine Sulfate extended-release tablets in the US. The medication is used to relieve severe and persistent pain. As per the USFDA, Princeton-based Dr Reddy's Laboratories Inc is recalling 2,040 bottles of 15 mg Morphine Sulfate extended-release tablets due to "Failed Impurities/Degradation Specification". The drugmaker is also recalling another 532 100-count bottles of the medication in 30 mg strength for the same reason, USFDA stated. Dr Reddy's initiated the Class II nationwide recall on October 22 this year. USFDA said Mumbai-headquartred FDC Ltd is recalling 1,55,232 bottles of Timolol Maleate ophthalmic solution in the US market. The company is recalling the .

Dr Reddy's clocks highest-ever revenue in Q2; net profit down 9.5%

Sequentially, revenue from operations grew by 4.5 per cent, whereas PAT declined by 3.6 per cent

Q2 results today: Titan, Mazagon, and Dr Reddy's among 63 to post earnings

Q2 results today, November 5: GAIL India, Oil India, Merger Paints, Mankind Pharma, and Saregama will be releasing their earnings report for the July-September quarter on Nov 5

Stocks To Watch: SBI, Mankind, Adani Enterprises, Dr. Reddy's, Zydus Life

Stocks to watch: SBI plans to open 600 new branches this fiscal year to expand its reach in emerging residential areas, said its chairman and managing director CS Setty.